Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 4/20 | 0.64 |
| ▸ | IL2 | P60568 | 3/20 | 0.64 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.55 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.55 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.55 |
| ▸ | ZAP70 | P43403 | 2/20 | 0.52 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.52 |
| ▸ | PRKCG | P05129 | 1/20 | 0.52 |
| ▸ | PRKCB | P05771 | 1/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | PRKCA | P17252 | 1/20 | 0.52 |
| ▸ | PRKCH | P24723 | 1/20 | 0.52 |
| ▸ | PRKCI | P41743 | 1/20 | 0.52 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.52 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.52 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.52 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.52 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.52 |
| ▸ | TGFBR1 | P36897 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6927694 | 0.90 | MAP4K1 (0.53) | MAP4K1IL2TLR8TLR7TLR9 | |
| SCHEMBL6926990 | 0.86 | ZAP70 (0.52) | MAP4K1IL2TLR8TLR7TLR9 | |
| SCHEMBL6925614 | 0.83 | TLR8 (0.60) | MAP4K1IL2TLR8TLR7TLR9 | |
| SCHEMBL6925715 | 0.83 | MAP4K1 (0.56) | MAP4K1IL2TLR8TLR7TLR9 | |
| SCHEMBL6928312 | 0.83 | MAP4K1 (0.48) | MAP4K1IL2TLR8TLR7TLR9 | |
| SCHEMBL6924500 | 0.81 | ATR (0.51) | MAP4K1IL2ACVR1BMPR1ARET | |
| SCHEMBL6920358 | 0.81 | CNR2 (0.52) | MAP4K1IL2ZAP70PRKD3EGFR | |
| SCHEMBL6929138 | 0.80 | FAAH (0.46) | MAP4K1IL2RET | |
| SCHEMBL6924654 | 0.80 | HDAC1 (0.50) | MAP4K1IL2TLR8TLR7TLR9 | |
| SCHEMBL30387478 | 0.78 | KDM4E (0.55) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6514966-B2 | Neuropeptide Y antagonists such as 2-chloro-5-(4-(3,4-dich loro-phenyl)-1H-imidazol-2-yl)-pyridine | PFIZER INC. | 2003-02-04 | — | — | US | disclosed |
| US-6355635-B1 | IMIDAZOLEBENZENE, IMIDAZOLEPYRIDINE COMPOUNDS FOR TREATMENT OF OBESITY | PFIZER INC. | 2002-03-12 | — | — | US | disclosed |
| US-20010039277-A1 | Compounds for the treatment of obesity | ELLIOTT RICHARD L (US) | 2001-11-08 | — | — | US | disclosed |
| WO-2000066578-A1 | COMPOUNDS FOR THE TREATMENT OF OBESITY | PFIZER PRODUCTS INC. (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039277-A1 | Compounds for the treatment of obesity | NPY1R, NPY4R, NPY2R | MAP4K1 1027/4885IL2 4689/4885TLR8 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.